Mannkind: Overlooked Biotech With Excellent Prospects (Part IV) [View article]
"$100 mil a Q, 3 Q's left in the year is $300 Mil...they only have $269Mil. They will be out of cash BEFORE the end of this year." -- Mr. BSG
As mentioned in the article, besides the $269 million in cash on hand, Mannkind also has a $350 million line of credit available from Al Mann, their CEO, on very favorable terms. That line of credit has not been drawn on at all as of now. Together that totals $619 million available to Mannkind before they have to start raising more money. Mannkind has repeatedly said that they have enough money to last them until the end of 2009 before they need more money (either through partnerships or through financing).
-
"$100 mil a Q, 3 Q's left in the year is $300 Mil...they only have $269Mil. They will be out of cash BEFORE the end of this year." -- Mr. BSG
Jun 18 20:25 pm
|Rating:
0
0
All Comments by Ahithophel Weissberger »Mannkind: Overlooked Biotech With Excellent Prospects (Part IV) [View article]
As mentioned in the article, besides the $269 million in cash on hand, Mannkind also has a $350 million line of credit available from Al Mann, their CEO, on very favorable terms. That line of credit has not been drawn on at all as of now. Together that totals $619 million available to Mannkind before they have to start raising more money. Mannkind has repeatedly said that they have enough money to last them until the end of 2009 before they need more money (either through partnerships or through financing).